Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | XDH | P47989 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | GFER | P55789 | 1/20 | 0.53 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.53 |
| ▸ | RELA | Q04206 | 1/20 | 0.53 |
| ▸ | FUT7 | Q11130 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 3/20 | 0.50 |
| ▸ | CA1 | P00915 | 3/20 | 0.50 |
| ▸ | CA2 | P00918 | 3/20 | 0.50 |
| ▸ | CA7 | P43166 | 3/20 | 0.50 |
| ▸ | CA9 | Q16790 | 3/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.50 |
| ▸ | KCNA3 | P22001 | 2/20 | 0.49 |
| ▸ | CNR2 | P34972 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31359551 | 1.00 | LMNA (0.53) | LMNAKDM4EXDHTDP1POLB | |
| SCHEMBL10069354 | 0.84 | KDM4E (0.42) | LMNAKDM4EXDHTDP1POLB | |
| SCHEMBL642064 | 0.83 | CA12 (0.54) | LMNAGAACA12CA1CA2 | |
| SCHEMBL18585480 | 0.83 | KDM4E (0.48) | LMNAKDM4EXDHTDP1POLB | |
| SCHEMBL18585559 | 0.80 | MAPT (0.47) | LMNAKDM4EXDHTDP1POLB | |
| SCHEMBL2653368 | 0.79 | RAB9A (0.44) | LMNAKDM4EXDHTDP1POLB | |
| SCHEMBL28371247 | 0.78 | ALDH1A1 (0.38) | LMNAKDM4EGAAL3MBTL1CA12 | |
| SCHEMBL8784780 | 0.76 | KDM4E (0.58) | KDM4EXDHCA12CA1CA2 | |
| SCHEMBL21527380 | 0.75 | KCNA3 (0.54) | LMNAKDM4EXDHPOLBGAA | |
| SCHEMBL2653764 | 0.74 | LMNA (0.53) | LMNAKDM4EXDHTDP1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121586712-A | Novel compounds | 豪夫迈·罗氏有限公司 | 2026-02-27 | — | — | CN | disclosed |
| WO-2025026882-A1 | NOVEL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2025-02-06 | — | — | WO | disclosed |
| US-7709505-B2 | Benzofuran derivatives, process for their preparation and intermediates thereof | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| EP-1578745-B1 | BENZOFURAN DERIVATivES, PROCESS FOR THEIR PREPARATION AND INTERMEDIATES THEREOF | ASTRAZENECA AB (SE) | 2007-11-14 | — | — | EP | disclosed |
| US-20060058353-A1 | Benzofuran derivatives, process for their preparation and intermediates thereof | ASTRAZENECA AB (SE) | 2006-03-16 | — | — | US | disclosed |
| EP-1578745-A1 | BENZOFURAN DERIVATES, PROCESS FOR THEIR PREPARATION AND INTERMEDIATES THEREOF | Astrazeneca AB (SE) | 2005-09-28 | — | — | EP | disclosed |
| WO-2004046139-A1 | BENZOFURAN DERIVATES, PROCESS FOR THEIR PREPARATION AND INTERMEDIATES THEREOF | ASTRAZENECA AB (SE) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058353-A1 | Benzofuran derivatives, process for their preparation and intermediates thereof | GCK, PDK2, GCKR | LMNA 1582/4885KDM4E 1766/4885XDH 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.